Reservoir Launches Personal Immune Cell Preservation Service for Adults

On October 15, 2026, autonomous cell manufacturing company Cellino launched Reservoir, a personal cell preservation service that allows adults to collect and store their own immune cells through a single standard blood draw. The service is currently available through partner clinics in San Francisco, Boston, Los Angeles, and New York City, alongside in-home appointment options rolling out in select markets.

Key Clinical Takeaways:
• Reservoir enables adults to preserve a biological sample of their immune cells via a standard blood draw at partner clinics or home appointments.
• The service stores isolated cells below −150°C in an FDA-registered facility, maintaining the member’s ownership and requiring physician coordination for release.
• Backed by Cellino’s $96 million in venture funding and an ARPA-H award of up to $25 million, the platform applies automated cell production to personal biological storage.

Blood Draws and Low-Temperature Storage at Partner Clinics

The collection process requires a single appointment with no fasting required. Patients undergo a standard blood draw at a partner clinic or through an in-home visit. Following collection, immune cells are isolated, counted, and cryopreserved under a standardized, documented process. The biological material is held below −150°C in an FDA-registered facility featuring continuous monitoring, automatic nitrogen fills, and backup power.

Pricing varies by partner clinic, covering the blood draw, cell isolation, and the first year of storage. Zip code lookups on the company website determine exact availability across New England, major metropolitan areas in California, New York, New Jersey, Florida, Texas, Georgia, and Washington.

Cellular Preservation versus Clinical Treatment

Reservoir operates strictly as a preservation service rather than a medical treatment. The company states that the service does not predict or promise any future clinical use. Immune cell populations fluctuate over a lifetime, meaning a sample collected today remains biologically distinct from cells gathered in later years.

“People are tracking more of their own health than ever, and they started asking us to preserve their cells,” said Nabiha Saklayen, co-founder of Reservoir and CEO of Cellino. “Wearables and blood tests capture today’s numbers. Reservoir captures today’s cells, the youngest your immune cells will ever be, carefully processed and reliably stored. We hold them. You own them.”

Physicians note that the service functions primarily to maintain biological optionality. “Patients come to us for guidance on longevity,” said Dr. Jay Luthar, a Harvard-trained physician on the faculty at Harvard Medical School and founder of Lutanen Health, one of the initial partner clinics. “Much of what is currently being marketed is unproven, or even has the potential to cause harm. Cell preservation is unique because it is fundamentally about optionality: preserving your cells as they are today, so that whatever the science makes possible later, you still have the material to use.”

Cellino Raises Funding to Develop Autonomous Manufacturing Technology

Reservoir was built by Cellino, a Cambridge, Massachusetts-based autonomous cell manufacturing company co-founded by Nabiha Saklayen and Marinna Madrid. The parent company has raised over $96 million in venture funding from backers including Khosla Ventures, 8VC, Felicis, Leaps by Bayer, and Engine Ventures. In addition to private backing, Cellino has received up to $25 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop its technology stack.

The FDA’s Center for Biologics Evaluation and Research granted Cellino an Advanced Manufacturing Technology designation. In 2021, the company won TechCrunch Disrupt’s Startup Battlefield. Alex Morgan, partner at Khosla Ventures, noted that banking cells captures a biological snapshot that cannot be replicated later. Dr. Michael Doney, executive medical director at Biograph, compared the approach to serial biomarker tracking, describing it as a strategy to preserve living cells before the accumulation of cellular aging.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.